相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cervical cancer prevention in Indonesia: An updated clinical impact, cost-effectiveness and budget impact analysis
Didik Setiawan et al.
PLOS ONE (2020)
Cost-effectiveness evaluations of the 9-Valent human papillomavirus (HPV) vaccine: Evidence from a systematic review
Rashidul Alam Mahumud et al.
PLOS ONE (2020)
HPV-FRAME: A consensus statement and quality framework for modelled evaluations of HPV-related cancer control
Karen Canfell et al.
PAPILLOMAVIRUS RESEARCH (2019)
Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines
Kine Pedersen et al.
EUROPEAN JOURNAL OF CANCER (2018)
Simultaneously characterizing the comparative economics of routine female adolescent nonavalent human papillomavirus (HPV) vaccination and assortativity of sexual mixing in Hong Kong Chinese: a modeling analysis
Horace C. W. Choi et al.
BMC MEDICINE (2018)
Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus
Jane J. Kim et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus
Jane J. Kim et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Human papillomavirus 9-valent vaccine for cancer prevention: a systematic review of the available evidence
C. Signorelli et al.
EPIDEMIOLOGY AND INFECTION (2017)
4-Valent Human Papillomavirus (4vHPV) Vaccine in Preadolescents and Adolescents After 10 Years
Daron G. Ferris et al.
PEDIATRICS (2017)
Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage
Triin Vorno et al.
VACCINE (2017)
Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy
Francesco Saverio Mennini et al.
COST EFFECTIVENESS AND RESOURCE ALLOCATION (2017)
Health and Economic Impact of Switching From a 4-Valent to a 9-Valent HPV Vaccination Program in the United States
Marc Brisson et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Health and Economic Impact of Switching From a 4-Valent to a 9-Valent HPV Vaccination Program in the United States
Marc Brisson et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria
L. Boiron et al.
BMC INFECTIOUS DISEASES (2016)
Impact and Cost-effectiveness of 3 Doses of 9-Valent Human Papillomavirus (HPV) Vaccine Among US Females Previously Vaccinated With 4-Valent HPV Vaccine
Harrell W. Chesson et al.
JOURNAL OF INFECTIOUS DISEASES (2016)
Response to Editorial: Estimating Health-State Utility for Economic Models in Clinical Studies: An ISPOR Good Research Practices Task Force Report
VALUE IN HEALTH (2016)
Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling analysis
Kate T. Simms et al.
LANCET PUBLIC HEALTH (2016)
A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women
E. A. Joura et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine
Melanie Drolet et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Human Papillomavirus Type Distribution in Invasive Cervical Cancer and High-Grade Cervical Intraepithelial Neoplasia Across 5 Countries in Asia
Swee Chong Quek et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2013)
Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis
Talia Malagon et al.
LANCET INFECTIOUS DISEASES (2012)
Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model
Mark Jit et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Epidemiologic Risk Profile of Infection With Different Groups of Human Papillomaviruses
Paul K. S. Chan et al.
JOURNAL OF MEDICAL VIROLOGY (2009)
Health and economic implications of HPV vaccination in the United States
Jane J. Kim et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Economic evaluation of human papillomavirus vaccination in the United Kingdom
Mark Jit et al.
BMJ-BRITISH MEDICAL JOURNAL (2008)
Abnormal outcomes following cervical cancer screening: Event duration and health utility loss
Ralph P. Insinga et al.
MEDICAL DECISION MAKING (2007)
Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine
Christophe Fraser et al.
VACCINE (2007)
Overview of the European and North American studies on HPV testing in primary cervical cancer screening
Jack Cuzick et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores
Janel Hanmer et al.
MEDICAL DECISION MAKING (2006)
Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance
JJ Kim et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
分享论文
